Looking at this in detail — TruFin is mid-transformation: they've just sold Playstack (the FY25 revenue engine) for £125m EV and are returning ~£78m to shareholders via a tender offer at 140p plus a 43p special dividend, leaving a much smaller continuing group of Oxygen (early-payment SaaS) and Satago (invoice-finance software) with ~£35m net cash and a stated platform-acquisition strategy.

TruFin plc (TRU) — Investment Research Note

Executive summary

TruFin is an AIM-listed holding company that, post the June 2026 disposal of Playstack, is a much smaller entity comprising Oxygen Finance (~85%-owned early-payment SaaS to UK local government) and Satago (~80%-owned invoice-finance software / LaaS platform), with £35m of pro-forma unrestricted cash and a stated strategy of acquiring "AI-resistant" platform businesses. Over the five years covered, the group pivoted from lending to recurring software / licensing (99% of 2025 revenue), delivered its first material profit in 2024 (Playstack driven), and crystallised value via the Playstack sale at ~9x FY25 EBITDA. The single most important valuation point today is that the current 134.5p share price precedes the 43p special dividend (ex-date 6 August 2026) and 140p tender consideration — most of the pre-tender market cap is imminent cash, so residual value in the continuing group is what matters.

Fair value estimate

• Fair value range: 150p – 180p per share (£139m – £167m market cap), mid ~165p.
• Methodology: Sum-of-parts on the current share (pre-distribution), = tender/dividend proceeds already committed + residual claim on continuing entity.
  • Cash post-distributions: £35m 2026-05 disposal circular
  • Oxygen at 10–12x FY25 EBITDA of £3.8m growing ~18%: £38–46m EV → TruFin's 85% = £32–39m 2026-03 final results
  • Satago residual value ~£5–10m (still loss-making but Sage/DF Capital partnerships alive; targeting break-even H1 2026) 2026-03 final results
  • Central overhead drag: –£3m capitalised
  • Continuing group NAV: ~£70–81m → 130–150p per pro-forma diluted share (52.9m fully diluted)
  • Add £70m tender + £22.5m dividend already being returned: total value per current share ~150–180p
• Vs. current 134.5p / £124.6m market cap: absolute upside ~12–34%, mid ~22%.

Sector context

Sector classification confirmed: Financials / Financial Services. This is not a typical financial services business — it's a small-cap holding-co with a public-sector fintech (Oxygen) and an SME fintech (Satago). Quality profile is above sector on balance-sheet strength (net cash after distributions), below on scale and profitability visibility. Listed peers in comparable niches: K3 Business Technology and Sopheon (UK vertical SaaS to public sector), Volution Group (small-cap platform acquirer model), and to a lesser extent Serica Investments-style holding companies. No perfect peer given the mid-transition state.

Investment thesis (3 bullets)

• Value crystallisation execution has been credible: Playstack was sold at £125m EV vs a business that generated £13.5m EBITDA in FY25, and management is returning ~£78m of the proceeds (~63% of pre-deal market cap) to shareholders directly rather than empire-building. Track record of two prior returns of capital (2019 tender at 92p, three buybacks in 2025-2026). 2026-05 disposal announcement, 2026-03 final results
• Oxygen is a genuine quality asset trapped inside a holding company: 7.7-year average client tenure, 100% renewals, >90% of the next five years' revenue already contracted, 65 EP clients, EBIT up 383% year-on-year in FY25 on 18% revenue growth — demonstrable operating leverage. Post-Playstack, Oxygen becomes 90%+ of continuing revenue. 2026-03 final results
• Balance sheet after distributions is fortress-like: pro-forma £35m unrestricted cash, no debt, no lending book to worry about, meaningful M&A optionality. Downside protection is real. 2026-05 disposal circular

Key risks (3 bullets)

• The stated go-forward strategy is deliberately anti-AI: management explicitly targets platforms "resilient to technological disruption including AI." That's the opposite of what an AI-receiver investor wants — they are actively selecting away from the thesis. 2026-05 disposal circular
• Continuing group is loss-making in 2026 and depends on an unproven M&A strategy (target: one new platform per year, one bolt-on per platform, £35m to deploy in 12 months, one candidate identified but not diligenced). Execution risk on capital deployment is the dominant continuing-group risk. 2026-05 disposal circular
• Satago's £5–10m value is speculative: FY25 revenue was £1.2m (–50% YoY after Lloyds lost the contract in 2024), still loss-making, break-even pushed to June 2026. Reliant on new partners converting from pipeline. 2026-03 final results

Operating leverage

Oxygen is the operating-leverage story: >98% of forecast 2026 EP revenue from existing clients, and 60%+ of clients cross-buy — so incremental revenue drops through with minimal variable cost. Illustrative: FY25 revenue up 18% to £9.1m, EBITDA up 57% to £3.8m, EBIT up 383% to £2.1m. Gross margins on the SaaS/Insights side are software-like; the EP fee-share model has a high fixed platform-cost base. A 15–20% revenue upside on Oxygen would plausibly add ~40–60% to Oxygen EBITDA. At group level this is diluted by Satago's fixed cost base of losses and holding-co overheads, so group-level leverage is more moderate. Satago is a classic pre-inflection software business — high fixed cost, low variable — where a Lloyds-type partner win would transform economics, but this is optionality rather than probable. 2026-03 final results, 2025-09 half-year

Value-trap signals

• Continuing group will be loss-making in 2026 with 2027 profitability being a target rather than a plan.
• Post-distribution free float will be thin (Watrium's stake rises to ~55% under Rule 9 waiver), which typically hurts liquidity and multiples.
• Historical track record of subsidiaries burning cash for years before profitability (Satago now targeting break-even for the third time; previously targeted 2021, 2024, now June 2026).
• Central cost base has not yet been resized for the much smaller continuing group.

Earnings vs. expectations

The five-year picture is strongly positive on this metric. Multiple upgrades during 2024 and 2025: January 2026 trading update raised PBT guidance again (>£7.4m vs prior guidance in December 2025 of >£7.0m); FY25 delivered PBT of £8.4m vs implicit expectations at start of 2025 that were far lower; FY24 landed materially ahead of the £(1.5)m LBT guided in December 2024, coming in at breakeven PBT and £7.6m EBITDA. Playstack's Balatro and Abiotic Factor drove the surprise. Consistent pattern of guiding conservatively and beating. However, this track record largely reflects Playstack, which is now being sold — so it does not necessarily apply to the continuing group. 2026-01, 2025-12, 2024-12, 2024-11 trading updates

Conviction

Conviction: 3 (moderate). Anchoring factors: (i) Playstack sale value is contractually agreed and cash-known; (ii) Oxygen's KPIs and operating-leverage evidence are well-disclosed and multi-year; (iii) mid-corporate-action means the tender and dividend cash components are quasi-certain. Limiting factors: (i) I am valuing a business that will look materially different in 12 months post platform-acquisition, and management have identified but not diligenced any target; (ii) Satago's residual value is a wide range and largely option-like.

Driver scoring

• ai_beneficiary: 20 — Management explicitly targets AI-resistant markets. Oxygen uses AI internally for procurement data capture but the value flows to Oxygen's clients, not shareholders. No demonstrable AI-driven revenue uplift the group itself captures. This is the wrong stock for the AI-receiver thesis.
• operating_leverage: 60 — Oxygen has genuine, demonstrated operating leverage (EBIT +383% on modest revenue growth); Satago has theoretical leverage; but group-level leverage is diluted by central costs and Satago losses on the small revenue base.
• earnings_surprise_trend: 75 — Multiple upward revisions across 2024 and 2025 driven by Playstack outperformance; consistent beat pattern.
• cyclicality: 30 — Oxygen's public-sector clients are structurally counter-cyclical (early-payment demand rises with fiscal pressure); Satago is more SME-exposed but small.
• moat: 55 — Oxygen has a genuine narrow moat (embedded local-authority integration, 7.7-yr tenure, 100% renewals, dominant market position). Continuing group weighted average is lower given Satago's undifferentiated position.
• leverage: 10 — Pro-forma net cash £35m, no debt. Fortress balance sheet.
• earnings_quality: 60 — Reported earnings have historically been supported by significant deferred tax credits and R&D tax credits; cash conversion at Oxygen is real, at Satago is negative. Materially cleaner going forward.
• management_quality: 65 — Consistent capital-allocation discipline over multiple cycles: two prior returns of capital, three buybacks in 12 months, disciplined Playstack sale process. Compensation is meaningful (CEO £1m+ in FY25) but tied to value creation.
• growth_momentum: 40 — On a continuing-group basis, Oxygen delivering 18% revenue growth and Satago rebuilding — but overall group revenue drops from £65.9m to ~£10m post-disposal, so headline momentum decelerates sharply.

overall_score: 300

This scores poorly against the investor's stated preferences. The AI-receiver pillar is essentially absent — management is explicitly positioning against AI exposure, not for it. Operating leverage exists but is meaningful only in a small subsidiary. Valuation offers 15–25% upside on my mid case, which is fair but not a value-anomaly. Balance sheet quality is excellent. Overall this is a well-run small-cap conglomerate returning capital sensibly — worth knowing exists, but not a fit for a portfolio designed around AI-driven operating leverage.